SCHEMBL29131908

SCHEMBL29131908

CC(C)(C)OC(=O)N1CCC[C@@H](Nc2nnc(Cl)c3ccncc23)C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 5/20 0.43
PIK3CD O00329 2/20 0.42
CYP2C9 P11712 1/20 0.42
BTK Q06187 2/20 0.42
PIM1 P11309 2/20 0.42
PIM2 Q9P1W9 2/20 0.42
ANO1 Q5XXA6 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
PARP1 P09874 1/20 0.40
KMT2A Q03164 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
PIK3CA P42336 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30624719 1.00 USP30 (0.43) USP30PIK3CDCYP2C9BTKPIM1
SCHEMBL26115440 1.00 USP30 (0.43) USP30PIK3CDCYP2C9BTKPIM1
SCHEMBL29276236 0.96 USP30 (0.43) USP30PIK3CDCYP2C9BTKPIM1
SCHEMBL30214807 0.96 USP30 (0.43) USP30PIK3CDCYP2C9BTKPIM1
SCHEMBL29276235 0.96 USP30 (0.43) USP30PIK3CDCYP2C9BTKPIM1
SCHEMBL31719493 0.91 JAK3 (0.44) BTKJAK2KMT2A
SCHEMBL25302213 0.90 USP30 (0.44) USP30PIK3CDCYP2C9BTKPIM1
SCHEMBL25302216 0.90 USP30 (0.44) USP30PIK3CDCYP2C9BTKPIM1
SCHEMBL31548626 0.90 USP30 (0.44) USP30PIK3CDCYP2C9BTKPIM1
SCHEMBL30108729 0.89 USP30 (0.50) USP30PIK3CDBTKPIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4644380-A1 PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2025-11-05 EP disclosed
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 US disclosed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 CN disclosed
WO-2024140824-A1 PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 长春金赛药业有限责任公司 2024-07-04 WO disclosed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 EP disclosed
CN-116969920-A Fused pyridazine derivative, preparation method and medical application thereof 上海辉启生物医药科技有限公司 2023-10-31 CN disclosed
WO-2023028534-A1 INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262806-A1 INHIBITORS OF NLRP3 NLRP3, NOD1, NLRP1 USP30 2086/4885PIK3CD 2031/4885CYP2C9 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.